STAR-T
Completed
818 enrolled
DeFianCe
Phase 2 Completed
188 enrolled
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
Phase 2 Completed
100 enrolled 13 charts
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
Phase 1/2 Completed
111 enrolled 22 charts
Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer
Phase 4 Completed
157 enrolled
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Phase 1 Completed
9 enrolled
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
90 enrolled 6 charts
CLIMB
Phase 2 Completed
20 enrolled
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Phase 2 Completed
247 enrolled 10 charts
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Phase 1 Completed
9 enrolled
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Phase 2 Completed
285 enrolled 31 charts
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
Phase 2 Completed
36 enrolled 8 charts
DEBIRI
Phase 1/2 Completed
70 enrolled 10 charts
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
145 enrolled
Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase 2 Completed
86 enrolled
1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer
Phase 2 Completed
102 enrolled
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Phase 3 Completed
2,334 enrolled 9 charts
G-CSF in Preventing Neutropenia During First-Line Treatment With Chemotherapy and Bevacizumab in Patients With Metastatic Colorectal Cancer
Phase 2 Completed
20 enrolled
Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer
Phase 2/3 Completed
492 enrolled
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
Phase 3 Completed
2,710 enrolled 8 charts
FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer
Phase 1/2 Completed
50 enrolled
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
Phase 2 Completed
130 enrolled 12 charts
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Phase 2 Completed
266 enrolled 17 charts
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Phase 3 Completed
847 enrolled 21 charts
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
Phase 1 Completed
20 enrolled
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Phase 1 Completed
17 enrolled
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Phase 1 Completed
23 enrolled
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Phase 1 Completed
180 enrolled
First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study
Phase NA Completed
100 enrolled
DREAM
Phase 3 Completed
700 enrolled
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
Phase 2 Completed
66 enrolled 7 charts
Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Phase 1 Completed
3 enrolled
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
Phase 2 Completed
70 enrolled
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Phase 2 Completed
50 enrolled 12 charts
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Phase 1/2 Completed
202 enrolled
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
Phase 2/3 Completed
3,240 enrolled
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
Phase 1 Completed
24 enrolled
Combination Chemotherapy Plus Bevacizumab in Treating Patients With Advanced Colorectal Cancer
Phase 2 Completed
Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy
Phase 2 Completed
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
Phase 3 Completed
880 enrolled
Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer
Phase 2 Completed
52 enrolled
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
Phase 1 Completed
17 enrolled
Avastin/[18-F]-5-fluorouracil PET/CT Imaging Feasibility Project
Completed
7 enrolled